Treats obsessive compulsive disorder (OCD). ANDA 219055, held by Ajanta Pharma Ltd. Fluvoxamine Maleate.
As of Nov 16, 2026, ANDA 219055 (Fluvoxamine Maleate), held by Ajanta Pharma Ltd, was first approved by FDA on Oct 17, 2024, with 0 approved supplements and 0 published complete response letters.
Fluvoxamine maleate extended-release capsules is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of obsessive compulsive disorder (OCD). Efficacy was demonstrated in: One 12-week study fluvoxamine maleate extended-release capsules in adults. Two 10-week studies with immediate-release (IR) fluvoxamine tablets in adults and one 10-week study with IR fluvoxamine tablets in children and adolescents ( 14.1, 14.3 ). One maintenance study with IR fluvoxamine tablets. 1.1 Obsessive Compulsive Disorder
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 17, 2024 | Original application | Approved | None posted |
| Fluvoxamine Maleate100MG · capsule, extended release;oral | Fluvoxamine Maleate | Rx |
| Fluvoxamine Maleate150MG · capsule, extended release;oral | Fluvoxamine Maleate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters